Jewellery expert reveals why rings should not be worn in gyms
Neil Ditta, a jewellery expert from Newcastle-Upon-Tyne-based store Angelic Diamonds, said people risk health problems, as well as losing their jewellery piece, if they wear their wedding, engagement or other rings whilst working out.
This includes getting rashes or infections as bacteria gets onto the piece of jewellery whilst working up a sweat.
He is quoted by MailOnline as saying: "Jewellery worn during exercise collects bacteria that can cause skin redness, rashes or infections.
"If your skin around the ring starts to look sore or inflamed, it is a clear sign to give your ring a break and clean it thoroughly."
As well as inflamed fingers, gymgoers with tight rings can also get swollen fingers, which is a "common" reason for people going to Accident and Emergency (A+E)
Neil added: "Swollen fingers combined with tight rings are a common cause of emergency visits to A E.
"It is an avoidable risk if you remove your ring before exercising."
Another reason to not wear rings in a gym is that workouts can "weaken" the ring's band, meaning it can easily fall off a person's finger.
He said: "The constant gripping and friction during workouts weakens the ring's band and can loosen stones.
"Damage may not be obvious straight away, but it builds up quickly over time."
And Neil stressed that high-intensity training exercises, such as push-ups and squats are not good for rings.
He explained: "High-intensity training is fantastic for fitness, but tough on rings,' Mr Ditta said.
"The combination of heavy weights and rapid motions increases the chance of your ring getting caught, knocked, or damaged.
"Functional training especially involves equipment and grips that can easily snag jewellery, so it is simply safer to leave rings at home during these sessions."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Courier-Mail
8 hours ago
- Courier-Mail
Doctors ignored 29-year-old's stage 4 cancer symptoms until it was too late
Don't miss out on the headlines from Celebrity Life. Followed categories will be added to My News. Jordan Brunoli, the bass player for Brisbane-based band Bugs, has opened up about being diagnosed with 'incurable' stage 4 colorectal cancer at just 29 years old. Brunoli discovered that the cancer had spread from his bowels to his liver and lymph nodes after doctors finally agreed to give him a scan. His bandmates have since created a GoFundMe page for his treatment. The band first broke the news to fans in a heartbreaking post on Instagram in June. They revealed that Brunoli was 'sent away from the emergency room and his GP repeatedly' after first showing symptoms. 'After months of constant pain Jordan was finally sent for a scan and diagnosed leaving his family in a state of shock'. Since then, the musician has had surgery to remove tumours from his bowel and lymph nodes. Doctors also created a stoma — an opening in his bowels to collect waste. A charity concert is being planned in Brisbane, and as word of Brunoli's diagnosis spreads many are sharing their shock and dismay that so many younger people are being affected by the disease. Jordan Brunoli, the bass player for Brisbane-based band Bugs, was diagnosed with "incurable" stage 4 cancer. Picture: Instagram The musician said that he has been 'getting used to living with a stoma'. 'Physically, this doesn't hold me back, I'm able to do 90 per cent of what I could before, just with a slightly higher risk of getting a hernia,' Brunoli said on his GoFundMe page. 'Not to be preachy, but if you have witnessed any blood in your stool, experienced weird abdominal pains, unexplained weight loss, or extended periods of fatigue — don't be afraid to raise it with your GP and ask for an abdominal ultrasound. 'I thought I was too young, but there has been a recent increase in instances of colorectal cancer in people under 30. 'Getting a diagnosis now could be the difference in a stage 1 tumour or stage 4 metastatic.' Colon cancer falls under the banner of bowel cancer, with the Royal Australian College of General Practitioners reporting that it was up 266 per cent from the 1980s among 15 to 24 year olds. The spike in bowel cancer cases is so worrying, the US Preventive Services Task Force changed its colorectal cancer screening guidelines in 2021 to lower the recommended age to start screening from 50 to 45 for those experiencing symptoms and those with a family history of colon cancer may be eligible earlier. Oncologists have partly blamed the concerning rise on obesity, a sedentary lifestyle, the Western diet, excess sugar consumption, and environmental factors such as pollutants in the air, soil, and water. Early detection can improve survival chances. Treatment often involves surgery to remove the tumour, chemotherapy and radiation therapy. So what are the warning signs to look out for? Changes in bowel habits: Persistent changes such as diarrhoea, constipation, or a feeling that the bowel does not empty completely. Blood in stool: This can appear as bright red blood or darker stools, indicating bleeding in the colon. Abdominal discomfort: Frequent gas pains, bloating, fullness, or cramps. Unexplained weight loss: Losing weight without trying can be a sign of colon cancer. Fatigue and weakness: Persistent tiredness that doesn't improve with rest. Narrow stools: Stools that are thinner than usual may indicate changes in the colon. Feeling of incomplete evacuation: A sensation that you need to have a bowel movement even after you've had one. Iron deficiency anaemia: Particularly in older adults, anaemia can be a result of bleeding from colon cancer. Originally published as Doctors ignored 29-year-old's stage 4 cancer symptoms until it was too late
Sydney Morning Herald
16 hours ago
- Sydney Morning Herald
Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant
To get an idea of where the real financial gravity sits within the Australian investing universe, CSL's market valuation plunge on Tuesday exceeded the entire $17 billion value of Qantas Airways with a billion or two to spare. It would be unfair to just blame this huge 15 per cent stock slump on its battles with the Trump administration. The biopharmaceutical giant has other challenges that were revealed on Tuesday with its full-year financial results and massive cost-cutting. But that should only add to the alarm for investors who may have noticed its outlook statement included the words: 'This guidance assumes no impact from pharmaceutical sector tariffs.' For the uninitiated, CSL's business is dominated by blood plasma products, but includes iron-deficiency-type treatments as well as vaccines. The vaccines company, Seqirus, will soon be spun off into a separately listed business. CSL chief executive Paul McKenzie put a brave face on Trump's threats to put tariffs up to 250 per cent on pharmaceuticals. This could affect $2 billion worth of Australian exports and the single biggest impact is expected to be on CSL's US exports, which are dominated by plasma products. Loading McKenzie pointed out to investors and analysts that most of the company's US business is sourced there, but the repeated questions from his audience say plenty about the market's nervousness. Especially when one question queried whether the Melbourne-based CSL was re-domiciling to the US. 'I'm not quite sure I relate to the re-domicile point. But just in general for tariffs, if you look at our plasma-derived products – as required from [US] regulatory, the plasma is sourced all in the US,' McKenzie said.
The Age
16 hours ago
- The Age
Trump's tariffs and anti-vaxxer clash with Australia's $130b health giant
To get an idea of where the real financial gravity sits within the Australian investing universe, CSL's market valuation plunge on Tuesday exceeded the entire $17 billion value of Qantas Airways with a billion or two to spare. It would be unfair to just blame this huge 15 per cent stock slump on its battles with the Trump administration. The biopharmaceutical giant has other challenges that were revealed on Tuesday with its full-year financial results and massive cost-cutting. But that should only add to the alarm for investors who may have noticed its outlook statement included the words: 'This guidance assumes no impact from pharmaceutical sector tariffs.' For the uninitiated, CSL's business is dominated by blood plasma products, but includes iron-deficiency-type treatments as well as vaccines. The vaccines company, Seqirus, will soon be spun off into a separately listed business. CSL chief executive Paul McKenzie put a brave face on Trump's threats to put tariffs up to 250 per cent on pharmaceuticals. This could affect $2 billion worth of Australian exports and the single biggest impact is expected to be on CSL's US exports, which are dominated by plasma products. Loading McKenzie pointed out to investors and analysts that most of the company's US business is sourced there, but the repeated questions from his audience say plenty about the market's nervousness. Especially when one question queried whether the Melbourne-based CSL was re-domiciling to the US. 'I'm not quite sure I relate to the re-domicile point. But just in general for tariffs, if you look at our plasma-derived products – as required from [US] regulatory, the plasma is sourced all in the US,' McKenzie said.
